Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE) appointed Dr. Stuart L. Goldstein as Director of Clinical Strategy on March 5, 2026, strengthening clinical leadership for its cardiorenal and pediatric focus.

Dr. Goldstein, a noted pediatric nephrology and critical care expert, will advise on product development, evidence generation, pediatric innovation, and educational initiatives to advance precision fluid management and AKI care.

Positive

• Seniority: Appointment of a leading pediatric nephrology expert strengthens clinical credibility
• Strategy: Direct support for pediatric innovation, evidence generation, and precision fluid management
• Clinical roadmap: Expected to guide product development and educational initiatives for cardiorenal care

Negative

• None.

Argus Mar 5 session

-5.13% close to close Open Argus

Details

News Market Reaction – NUWE

On Mar 5, the day this news came out, NUWE closed 5.13% below the previous close.

Data tracked by StockTitan Argus for the Mar 5 session.

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Board appointments

   24h Move

   -3.6%

   Added experienced directors to support strategic execution and capital markets access.

2. Feb 24

   Earnings date set

   24h Move

   -4.7%

   Scheduled Q4 and full-year 2025 results call and business update.

3. Jan 30

   CFO appointment

   24h Move

   -10.0%

   Named a new CFO with medical-technology and public company finance experience.

4. Jan 29

   Private placement

   24h Move

   -10.0%

   Announced a $5.0M priced-at-the-market private placement and warrant inducement.

5. Jan 29

   Acquisition deal

   24h Move

   -10.0%

   Agreed to acquire Rendiatech to expand real-time kidney function monitoring portfolio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

acute kidney injury, continuous renal replacement therapies, fluid overload, hemodynamic stability, +2 more

6 terms

acute kidney injury medical

"His work has helped define the modern understanding of acute kidney injury (AKI),"

A sudden decline in how well the kidneys remove waste and balance fluids, often developing over hours or days; think of it like an engine that abruptly loses power and can’t filter efficiently. It matters to investors because it can drive higher medical costs, alter clinical trial results, trigger regulatory scrutiny, lead to drug label changes or recalls, and affect revenue and liability for healthcare and life sciences companies.

continuous renal replacement therapies medical

"and the use of continuous renal replacement therapies in critically ill children."

Continuous renal replacement therapies are medical treatments that gently and continuously filter a patient’s blood to remove waste and excess fluid when the kidneys are failing, typically used in intensive care. For investors, these therapies represent a market for specialized machines, disposable filters and hospital services whose demand is driven by critical-care caseloads, device adoption, reimbursement and outcomes—think of it as a slow, steady water filter for the bloodstream rather than a periodic cleaning.

fluid overload medical

"relationship between fluid overload and mortality in critically ill pediatric patients,"

Fluid overload is an excess buildup of fluid in the body that can cause swelling, shortness of breath, and strain on the heart and lungs — like overwatering a sponge so it bulges and drips. It matters to investors because it drives demand for treatments, affects hospital length of stay and costs, can create safety risks in clinical trials, and therefore influences revenue, regulatory scrutiny, and valuation for healthcare companies.

hemodynamic stability medical

"designed to safely remove excess fluid while preserving hemodynamic stability."

Hemodynamic stability means a patient’s heart and blood vessels are maintaining steady blood flow, blood pressure, and organ perfusion so tissues get the oxygen and nutrients they need. For investors, it matters because treatments or procedures that improve or jeopardize this balance can change hospital stays, complication rates, regulatory assessments, and the commercial outlook for drugs or devices—much like steady water pressure indicates a healthy plumbing system.

ultrafiltration medical

"strategy centers on early identification of fluid overload, precision ultrafiltration,"

Ultrafiltration is a process that separates small particles and liquids from larger molecules or substances using a filter with tiny pores. It is often used in water treatment and medical applications to remove impurities or excess fluids. For investors, understanding ultrafiltration is important because innovations or changes in this technology can impact industries focused on clean water, healthcare, and filtration products.

cardiorenal medical

"company’s evolving cardiorenal focus."

Cardiorenal describes the close connection between the heart and kidneys, including conditions where disease in one organ directly affects the other — like a pump and filter that rely on each other to keep the system balanced. Investors care because treatments, diagnostics, or drugs that target this interaction can address multiple health problems at once, influencing market size, regulatory scrutiny, clinical trial complexity, and potential returns in healthcare and biotech sectors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury

MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy.

Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understanding of acute kidney injury (AKI), fluid overload, and the use of continuous renal replacement therapies in critically ill children.

Dr. Goldstein’s research has been foundational in demonstrating the relationship between fluid overload and mortality in critically ill pediatric patients, including landmark studies through the Prospective Pediatric Continuous Renal Replacement Therapy Registry. His work has significantly shaped global standards for early identification and management of AKI and fluid balance in critically ill populations.

As Director of Clinical Strategy , Dr. Goldstein will consult with and advise Nuwellis on clinical feedback, product development, pediatric innovation, evidence generation, and educational initiatives aligned with the company’s evolving cardiorenal focus. His expertise will directly support Nuwellis’ commitment to advancing precision fluid management solutions that address the critical interplay between the heart and kidneys across the continuum of care.

“Our cardiorenal strategy is rooted in the science of fluid balance and the clinical consequences of fluid overload,” said Kelsey Newell, Sr. Director of Medical Affairs at Nuwellis. “Dr. Goldstein’s pioneering work in pediatric AKI and fluid management has shaped how the medical community understands the impact of fluid overload on outcomes. His insight will strengthen our clinical evidence roadmap, guide responsible innovation, and ensure our technologies are aligned with the needs of critically ill children and adults.”

Dr. Goldstein added, “Fluid overload remains one of the most important modifiable risk factors in critically ill patients, yet it is often addressed too late or with limited precision. Nuwellis is focused on advancing technologies that allow clinicians to intervene earlier and manage volume status more thoughtfully. I look forward to working with the team to help generate evidence, educate clinicians, and support a more proactive cardiorenal approach to care.”

Nuwellis’ cardiorenal strategy centers on early identification of fluid overload, precision ultrafiltration, and technologies designed to safely remove excess fluid while preserving hemodynamic stability. The company continues to expand its clinical and scientific partnerships to drive better outcomes for patients with heart failure, acute kidney injury, and complex cardiorenal conditions.

For more information, visit www.nuwellis.com.

About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company advancing precision fluid management technologies across the cardiorenal continuum. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations.

About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:
ir@nuwellis.com

Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Dr. Stuart L. Goldstein and what role did he accept at Nuwellis (NUWE)?

Dr. Stuart L. Goldstein accepted the role of Director of Clinical Strategy at Nuwellis. According to Nuwellis, he is a pediatric nephrology and critical care leader who will advise on clinical feedback, product development, evidence generation, and pediatric innovation.

How will Dr. Goldstein’s appointment affect Nuwellis’ cardiorenal strategy (NUWE)?

It will strengthen Nuwellis’ clinical evidence and product guidance for cardiorenal care. According to Nuwellis, Dr. Goldstein will shape the clinical evidence roadmap, guide responsible innovation, and align technologies with needs of critically ill children and adults.

What pediatric expertise does Dr. Goldstein bring to Nuwellis (NUWE)?

Dr. Goldstein brings foundational work on AKI, fluid overload, and continuous renal replacement therapies. According to Nuwellis, his research helped define early identification and management of fluid overload in critically ill pediatric patients.

Will Dr. Goldstein advise on product development and clinical evidence at Nuwellis (NUWE)?

Yes — he will consult on product development and evidence generation to advance precision ultrafiltration tools. According to Nuwellis, his role includes advising on clinical feedback, pediatric innovation, and educational initiatives supporting cardiorenal solutions.

What clinical priorities will Nuwellis (NUWE) pursue with Dr. Goldstein’s guidance?

Priorities include early identification of fluid overload, precision ultrafiltration, and safe fluid removal while maintaining stability. According to Nuwellis, Dr. Goldstein will support evidence generation and clinician education to enable a proactive cardiorenal approach.